Comments
Loading...

Avadel Pharmaceuticals Analyst Ratings

AVDLNASDAQ
Logo brought to you by Benzinga Data
Consensus Rating1
Buy
Highest Price Target1
$30.00
Lowest Price Target1
$11.00
Consensus Price Target1
$17.91

Avadel Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:AVDL | Benzinga

Avadel Pharmaceuticals PLC has a consensus price target of $17.91 based on the ratings of 11 analysts. The high is $30 issued by Oppenheimer on October 31, 2024. The low is $11 issued by Jefferies on November 30, 2022. The 3 most-recent analyst ratings were released by Needham on May 8, 2025, April 9, 2025, and March 4, 2025, respectively. With an average price target of $19 between Needham, there's an implied 104.52% upside for Avadel Pharmaceuticals PLC from these most-recent analyst ratings.

Analyst Trends and Forecast
4
Jan
1
Feb
3
Mar
1
Apr
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Needham
HC Wainwright & Co.
Deutsche Bank
UBS
Piper Sandler

1calculated from analyst ratings

Analyst Ratings for Avadel Pharmaceuticals

Buy NowGet Alert
05/08/2025Buy Now104.52%Needham
Ami Fadia54%
$19 → $19ReiteratesBuy → BuyGet Alert
04/09/2025Buy Now104.52%Needham
Ami Fadia54%
$19 → $19ReiteratesBuy → BuyGet Alert
03/04/2025Buy Now104.52%Needham
Ami Fadia54%
$19 → $19ReiteratesBuy → BuyGet Alert
03/04/2025Buy Now126.05%HC Wainwright & Co.
Oren Livnat60%
$21 → $21ReiteratesBuy → BuyGet Alert
03/03/2025Buy Now104.52%Needham
Ami Fadia54%
$19 → $19ReiteratesBuy → BuyGet Alert
02/11/2025Buy Now29.17%Deutsche Bank
David Hoang39%
→ $12Initiates → BuyGet Alert
01/13/2025Buy Now50.7%UBS
Ashwani Verma46%
$22 → $14MaintainsBuyGet Alert
01/10/2025Buy Now39.94%Piper Sandler
David Amsellem72%
$24 → $13MaintainsOverweightGet Alert
01/10/2025Buy Now126.05%HC Wainwright & Co.
Oren Livnat60%
$25 → $21ReiteratesBuy → BuyGet Alert
01/09/2025Buy Now104.52%Needham
Ami Fadia54%
$22 → $19MaintainsBuyGet Alert
11/13/2024Buy Now169.11%HC Wainwright & Co.
Oren Livnat60%
$27 → $25MaintainsBuyGet Alert
11/13/2024Buy Now136.81%Needham
Ami Fadia54%
$22 → $22ReiteratesBuy → BuyGet Alert
11/12/2024Buy Now136.81%Needham
Ami Fadia54%
$22 → $22ReiteratesBuy → BuyGet Alert
10/31/2024Buy Now190.64%HC Wainwright & Co.
Oren Livnat60%
$27 → $27ReiteratesBuy → BuyGet Alert
10/31/2024Buy Now222.93%Oppenheimer
Francois Brisebois40%
$29 → $30MaintainsOutperformGet Alert
10/31/2024Buy Now136.81%Needham
Ami Fadia54%
$22 → $22ReiteratesBuy → BuyGet Alert
10/21/2024Buy Now190.64%HC Wainwright & Co.
Oren Livnat60%
$27 → $27ReiteratesBuy → BuyGet Alert
10/18/2024Buy Now136.81%Needham
Ami Fadia54%
$22 → $22ReiteratesBuy → BuyGet Alert
09/04/2024Buy Now136.81%Needham
Ami Fadia54%
$22 → $22ReiteratesBuy → BuyGet Alert
08/29/2024Buy Now136.81%Needham
Ami Fadia54%
$22 → $22ReiteratesBuy → BuyGet Alert
08/28/2024Buy Now190.64%HC Wainwright & Co.
Oren Livnat60%
$27 → $27ReiteratesBuy → BuyGet Alert
08/09/2024Buy Now136.81%Needham
Ami Fadia54%
$22 → $22ReiteratesBuy → BuyGet Alert
05/09/2024Buy Now136.81%Needham
Ami Fadia54%
$22 → $22ReiteratesBuy → BuyGet Alert
05/09/2024Buy Now190.64%HC Wainwright & Co.
Oren Livnat60%
$25 → $27MaintainsBuyGet Alert
05/09/2024Buy Now147.58%Craig-Hallum
Chase Knickerbocker58%
$22 → $23MaintainsBuyGet Alert
05/08/2024Buy Now136.81%Needham
Ami Fadia54%
$22 → $22ReiteratesBuy → BuyGet Alert
04/09/2024Buy Now136.81%Needham
Ami Fadia54%
$22 → $22ReiteratesBuy → BuyGet Alert
03/05/2024Buy Now136.81%Craig-Hallum
Chase Knickerbocker58%
$20 → $22MaintainsBuyGet Alert
03/05/2024Buy Now147.58%Piper Sandler
David Amsellem72%
$18 → $23MaintainsOverweightGet Alert
03/05/2024Buy Now212.16%Oppenheimer
Francois Brisebois40%
$27 → $29MaintainsOutperformGet Alert
03/05/2024Buy Now169.11%HC Wainwright & Co.
Oren Livnat60%
$21 → $25MaintainsBuyGet Alert
03/05/2024Buy Now136.81%Needham
Ami Fadia54%
$20 → $22MaintainsBuyGet Alert
02/06/2024Buy Now126.05%UBS
Ashwani Verma46%
→ $21Initiates → BuyGet Alert
12/20/2023Buy Now115.29%Needham
Ami Fadia54%
$19 → $20MaintainsBuyGet Alert
11/09/2023Buy Now104.52%Needham
Ami Fadia54%
$18 → $19MaintainsBuyGet Alert
10/04/2023Buy Now93.76%Needham
Ami Fadia54%
→ $18ReiteratesBuy → BuyGet Alert
09/25/2023Buy Now93.76%Needham
Ami Fadia54%
→ $18ReiteratesBuy → BuyGet Alert
08/10/2023Buy Now93.76%Piper Sandler
David Amsellem72%
$13 → $18MaintainsOverweightGet Alert
08/10/2023Buy Now93.76%Needham
Ami Fadia54%
→ $18ReiteratesBuy → BuyGet Alert
08/10/2023Buy Now126.05%HC Wainwright & Co.
Oren Livnat60%
→ $21ReiteratesBuy → BuyGet Alert
08/09/2023Buy Now93.76%Needham
Ami Fadia54%
→ $18Reiterates → BuyGet Alert
07/05/2023Buy Now126.05%HC Wainwright & Co.
Oren Livnat60%
$17.5 → $21ReiteratesBuy → BuyGet Alert
06/30/2023Buy Now169.11%Oppenheimer
Francois Brisebois40%
$22 → $25MaintainsMarket OutperformGet Alert
06/30/2023Buy Now93.76%Needham
Ami Fadia54%
→ $18ReiteratesBuy → BuyGet Alert
06/12/2023Buy Now136.81%Oppenheimer
Francois Brisebois40%
→ $22ReiteratesOutperform → OutperformGet Alert
05/30/2023Buy Now93.76%Needham
Ami Fadia54%
$14 → $18Reiterates → BuyGet Alert
05/02/2023Buy Now179.87%LifeSci Capital
Patrick Dolezal69%
$17 → $26MaintainsOutperformGet Alert
05/02/2023Buy Now72.23%Ladenburg Thalmann
Matthew Kaplan65%
$14.5 → $16MaintainsBuyGet Alert
05/02/2023Buy Now136.81%Oppenheimer
Francois Brisebois40%
$20 → $22MaintainsOutperformGet Alert
05/02/2023Buy Now88.37%HC Wainwright & Co.
Oren Livnat60%
$14 → $17.5MaintainsBuyGet Alert
05/02/2023Buy Now50.7%Needham
Ami Fadia54%
$12 → $14MaintainsBuyGet Alert
04/28/2023Buy Now29.17%Needham
Ami Fadia54%
→ $12Reiterates → BuyGet Alert
04/17/2023Buy Now18.41%Needham
Ami Fadia54%
→ $11MaintainsBuyGet Alert
04/03/2023Buy Now115.29%Oppenheimer
Francois Brisebois40%
→ $20Reiterates → OutperformGet Alert
04/03/2023Buy Now18.41%Needham
Ami Fadia54%
→ $11Reiterates → BuyGet Alert
03/23/2023Buy Now50.7%HC Wainwright & Co.
Oren Livnat60%
$13 → $14MaintainsBuyGet Alert
02/27/2023Buy Now115.29%Oppenheimer
Francois Brisebois40%
$19 → $20MaintainsOutperformGet Alert
02/24/2023Buy Now18.41%Needham
Ami Fadia54%
→ $11MaintainsBuyGet Alert
02/07/2023Buy Now39.94%HC Wainwright & Co.
Oren Livnat60%
→ $13Reiterates → BuyGet Alert
02/07/2023Buy Now18.41%Needham
Ami Fadia54%
→ $11Reiterates → BuyGet Alert
11/30/2022Buy Now18.41%Jefferies
Chris Howerton62%
$6.5 → $11UpgradeHold → BuyGet Alert
11/21/2022Buy Now-3.12%Needham
Ami Fadia54%
$8 → $9MaintainsBuyGet Alert
08/11/2022Buy Now29.17%SVB Leerink
Marc Goodman72%
$6 → $12MaintainsOutperformGet Alert
08/10/2022Buy Now-3.12%Needham
Ami Fadia54%
$6 → $9MaintainsBuyGet Alert
08/10/2022Buy Now-13.89%Jefferies
Chris Howerton62%
$6 → $8DowngradeBuy → HoldGet Alert
05/31/2022Buy Now-35.41%Needham
Ami Fadia54%
$14 → $6MaintainsBuyGet Alert
05/27/2022Buy Now39.94%HC Wainwright & Co.
Oren Livnat60%
$17 → $13MaintainsBuyGet Alert
05/27/2022Buy Now-35.41%SVB Leerink
Marc Goodman72%
$18 → $6MaintainsOutperformGet Alert

FAQ

Q

What is the target price for Avadel Pharmaceuticals (AVDL) stock?

A

The latest price target for Avadel Pharmaceuticals (NASDAQ:AVDL) was reported by Needham on May 8, 2025. The analyst firm set a price target for $19.00 expecting AVDL to rise to within 12 months (a possible 104.52% upside). 22 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Avadel Pharmaceuticals (AVDL)?

A

The latest analyst rating for Avadel Pharmaceuticals (NASDAQ:AVDL) was provided by Needham, and Avadel Pharmaceuticals reiterated their buy rating.

Q

When was the last upgrade for Avadel Pharmaceuticals (AVDL)?

A

The last upgrade for Avadel Pharmaceuticals PLC happened on November 30, 2022 when Jefferies raised their price target to $11. Jefferies previously had a hold for Avadel Pharmaceuticals PLC.

Q

When was the last downgrade for Avadel Pharmaceuticals (AVDL)?

A

The last downgrade for Avadel Pharmaceuticals PLC happened on August 10, 2022 when Jefferies changed their price target from $6 to $8 for Avadel Pharmaceuticals PLC.

Q

When is the next analyst rating going to be posted or updated for Avadel Pharmaceuticals (AVDL)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avadel Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avadel Pharmaceuticals was filed on May 8, 2025 so you should expect the next rating to be made available sometime around May 8, 2026.

Q

Is the Analyst Rating Avadel Pharmaceuticals (AVDL) correct?

A

While ratings are subjective and will change, the latest Avadel Pharmaceuticals (AVDL) rating was a reiterated with a price target of $19.00 to $19.00. The current price Avadel Pharmaceuticals (AVDL) is trading at is $9.29, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.